ArticleGene therapy2018

Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9.

Calvin J Stephens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.